Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program

BACKGROUND: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We present integrated analyses of nonmelanoma skin cancer (NMSC) incidence in the tofacitinib UC clinical program. METHODS: Nonmelanoma skin cancer events were evaluated from 3 ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Sands, Bruce E, Long, Millie D, Reinisch, Walter, Panés, Julian, Loftus, Edward V, Nduaka, Chudy I, Soonasra, Arif, Mundayat, Rajiv, Lawendy, Nervin, Chan, Gary, Friedman, Gary S, Su, Chinyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804509/
https://www.ncbi.nlm.nih.gov/pubmed/33742652
http://dx.doi.org/10.1093/ibd/izab056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804509/
https://www.ncbi.nlm.nih.gov/pubmed/33742652
http://dx.doi.org/10.1093/ibd/izab056

Ejemplares similares